false
zh-CN,zh-TW,en,fr,de,hi,ja,ko,pt,es
Catalog
Revolutionizing Type 1 Diabetes Care through Advan ...
Clinical Treatment and Management Following Screen ...
Clinical Treatment and Management Following Screening
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Alex Tuttle discusses monitoring pre-stage 3 type 1 diabetes primarily to prevent diabetic ketoacidosis and reduce healthcare costs. Monitoring assists in optimal insulin initiation timing, preventing misdiagnosis, and facilitating clinical trial participation. An international consensus statement on monitoring individuals with pre-stage 3 type 1 diabetes was published, guided by experts and endorsed by global organizations. The guidance addresses various healthcare providers responsible for antibody screening, testing, and monitoring. The presentation emphasizes individualized monitoring, education, and psychosocial support to manage early-stage type 1 diabetes, highlighting a tailored approach for pediatric and adult patients.
Keywords
type 1 diabetes
diabetic ketoacidosis
insulin initiation
antibody screening
individualized monitoring
EndoCareers
|
Contact Us
|
Privacy Policy
|
Terms of Use
CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036
202.971.3636 | 888.363.6274
×